Themesothelioma News

Friday, August 30, 2019

Drugs Approved for Melanoma - National Cancer Institute

Drugs Approved for Melanoma - National Cancer Institute

National Cancer Institute

Drugs Approved for Melanoma

This page lists cancer drugs approved by the Food and Drug Administration (FDA) for melanoma. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. There may be drugs used in melanoma that are not listed here.

Drugs Approved for Melanoma

  • Aldesleukin
  • Binimetinib
  • Braftovi (Encorafenib)
  • Cobimetinib
  • Cotellic (Cobimetinib)
  • Dabrafenib Mesylate
  • Dacarbazine
  • Encorafenib
  • IL-2 (Aldesleukin)
  • Imlygic (Talimogene Laherparepvec)
  • Interleukin-2 (Aldesleukin)
  • Intron A (Recombinant Interferon Alfa-2b)
  • Ipilimumab
  • Keytruda (Pembrolizumab)
  • Mekinist (Trametinib)
  • Mektovi (Binimetinib)
  • Nivolumab
  • Opdivo (Nivolumab)
  • Peginterferon Alfa-2b
  • PEG-Intron (Peginterferon Alfa-2b)
  • Pembrolizumab
  • Proleukin (Aldesleukin)
  • Recombinant Interferon Alfa-2b
  • Sylatron (Peginterferon Alfa-2b)
  • Tafinlar (Dabrafenib Mesylate)
  • Talimogene Laherparepvec
  • Trametinib
  • Vemurafenib
  • Yervoy (Ipilimumab)
  • Zelboraf (Vemurafenib)
Related Resources
  • Skin Cancer (Including Melanoma)—Patient Version
  • Chemotherapy and You: Support for People With Cancer
  • Updated: June 10, 2019
Posted by EH at 7:17 AM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

Infolinks

About Me

EH
View my complete profile

Blog Archive

  • ►  2020 (1429)
    • ►  December (7)
    • ►  November (4)
    • ►  October (3)
    • ►  September (7)
    • ►  August (7)
    • ►  July (4)
    • ►  June (10)
    • ►  May (10)
    • ►  April (7)
    • ►  March (303)
    • ►  February (606)
    • ►  January (461)
  • ▼  2019 (5018)
    • ►  December (579)
    • ►  November (501)
    • ►  October (464)
    • ►  September (449)
    • ▼  August (528)
      • Immunization Works August 2019 Newsletter | CDC
      • Preparing for a Hurricane or Tropical Storm | Feat...
      • Healthy Food Choices Made Easy
      • How Will This Impact My Baby
      • Blood Sugar Testing and Control
      • Nutrition Overview
      • What Are My Options?
      • Steps to Prevent or Delay Nerve Damage
      • Paying for Medical Care | USAGov
      • Prepare Your Health | CDC
      • CDC Health Alert Network (HAN) Health Advisory: Se...
      • CDC Releases Additional STEM Educational Activitie...
      • Prevention and Control of Seasonal Influenza with ...
      • National HIV/AIDS and Aging Awareness Day #HIVandA...
      • Data to Care | HIV.gov
      • GenBank release 233 | NCBI Insights
      • the people that justify our existence ► https://th...
      • EL BIRUNI: CIENCIAS MÉDICAS NEWS [https://themesot...
      • The family planning quotient and reproductive life...
      • Assessing the impact of an educational interventio...
      • Discrepancy in perception of infertility and attit...
      • Sexuality and contraceptive knowledge in universit...
      • Challenges to access health information during pre...
      • Fertility and family planning in Uttar Pradesh, In...
      • Contraceptive discontinuation: frequency and assoc...
      • Mistreatment of women in public health facilities ...
      • Characterization of an immortalized human small ai...
      • Meet our Docs: Jeremy Davis, M.D.
      • Immunization-related MMWRs | CDC
      • Notes from the Field: Mumps in Detention Facilitie...
      • Racial Disparities in Breastfeeding Initiation and...
      • QuickStats: Percentage of Currently Employed Adult...
      • Notes from the Field: Multistate Outbreak of Salmo...
      • Changes in Opioid-Involved Overdose Deaths by Opio...
      • International Overdose Awareness Day — August 31, ...
      • Effect of Pneumococcal Conjugate Vaccines on Pneum...
      • 2018 NCVRW Resource Guide: Intimate Partner Violen...
      • Types of Primary Immune Deficiency Diseases | NIH:...
      • Drugs Approved for Vulvar Cancer - National Cancer...
      • Drugs Approved for Thyroid Cancer - National Cance...
      • Drugs Approved for Testicular Cancer - National Ca...
      • Drugs Approved for Stomach (Gastric) Cancer - Nati...
      • Drugs Approved for Solid Tumors Anywhere in the Bo...
      • Drugs Approved for Prostate Cancer - National Canc...
      • Drugs Approved for Penile Cancer - National Cancer...
      • Drugs Approved for Pancreatic Cancer - National Ca...
      • Drugs Approved for Ovarian, Fallopian Tube, or Pri...
      • Drugs Approved for Multiple Myeloma - National Can...
      • Drugs Approved for Non-Hodgkin Lymphoma - National...
      • Drugs Approved for Melanoma - National Cancer Inst...
      • Drugs Approved for Lung Cancer - National Cancer I...
      • Drugs Approved for Liver Cancer - National Cancer ...
      • Drugs Approved for Leukemia - National Cancer Inst...
      • Drugs Approved for Kaposi Sarcoma - National Cance...
      • Drugs Approved for Kidney (Renal Cell) Cancer - Na...
      • Drugs Approved for Hodgkin Lymphoma - National Can...
      • Drugs Approved for Head and Neck Cancer - National...
      • Drugs Approved for Colon and Rectal Cancer - Natio...
      • Drugs Approved for Cervical Cancer - National Canc...
      • Drugs Approved for Breast Cancer - National Cancer...
      • Drugs Approved for Brain Tumors - National Cancer ...
      • Drugs Approved for Bladder Cancer - National Cance...
      • Cancer Drugs - National Cancer Institute
      • Immunotherapy in People with Cancer and Autoimmune...
      • Pembrolizumab Approved for Esophageal Cancer - Nat...
      • Clinical Trials Update from NCI, August 2019
      • Varicose veins | Migraine Trainer app | Aspirin us...
      • Call for Manuscripts on Structural Racism/Discrimi...
      • Information for Eye Care Providers & Public Health...
      • CDC-INFO on Demand - Publications
      • Germs & Infections | Contact Lenses | CDC
      • Healthy Contact Lens Behaviors Communicated by Eye...
      • Protect Your Eyes | Contact Lenses | CDC
      • Delaying Dementia: The New Guidelines - Ivanhoe Br...
      • National Institute of Allergy and Infectious Disea...
      • Hypertension (High Blood Pressure) | NCCIH
      • Podcast: Overlooked women in science, Huntington's...
      • EL BIRUNI: CIENCIAS MÉDICAS NEWS [https://themesot...
      • Lack Of Diversity In Genetic Databases Hampers Res...
      • Team links gene to children with physical and inte...
      • The Genome Empowerment Scale (GEmS): An Assessment...
      • [Pay attention to rare diseases of the genetic cou...
      • Leveraging European infrastructures to access 1 mi...
      • Low-pass genome sequencing versus chromosomal micr...
      • Congenital Heart Disease: Prenatal Diagnosis and G...
      • Emerging non-genetic therapies for sickle cell dis...
      • Detection of PMS2 Mutations by Screening Hereditar...
      • Applications of liquid biopsies for cancer A Matt...
      • Germline pathogenic variants in BRCA1, BRCA2, PALB...
      • Inherited cancer syndromes in 220 Italian ovarian ...
      • USPSTF Recommendation Expands Cancer Screening Poo...
      • Biobanking Is Changing The World J Pandya, Forbes...
      • Facial recognition software in clinical dysmorphol...
      • Exome sequencing of 457 autism families recruited ...
      • Deep Learning and Neurology: A Systematic Review. ...
      • Pathogen Genomics: Empowering Infectious Disease S...
      • Using Electronic Health Records and Machine Learni...
      • Can Lifestyle Choices Offset Dementia Risk Genes? ...
      • Recognition of Board-Certified Clinical Laboratory...
      • Association of Multifaceted Mobile Technology–Enab...
    • ►  July (372)
    • ►  June (450)
    • ►  May (475)
    • ►  April (300)
    • ►  March (450)
    • ►  February (450)
  • ►  2008 (1)
    • ►  August (1)
Powered by Blogger.